·Tasigna 150mg and 200mg are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (CML) in the chronic phase.
·Tasigna 200mg only is indicated also for the treatment of Philadelphia
chromosome positive chronic myeloid leukaemia (Ph+CML) in chronic phase
or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib
The recommended dose of Tasigna is :
·300 mg twice daily in newly diagnosed patients with CML in the chronic phase
·400 mg twice daily in patients with chronic or accelerated phase CML with resistance or intolerance to prior therapy with imatinib